Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Authors

Showing 10 results for author "Maher Salamoon".

Back to authors

Thumbnail for The emerging role of Venetoclax in high risk newly diagnosed patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

ALL - 642

The emerging role of Venetoclax in high risk newly diagnosed patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for The Role of Blinatumomab in CD19-Positive Precursor B-Cell Acute Lymphoblastic Leukemia Philadelphia-Negative Disease: A 3-Year Update on Progression-Free Survival

ALL - 840

The Role of Blinatumomab in CD19-Positive Precursor B-Cell Acute Lymphoblastic Leukemia Philadelphia-Negative Disease: A 3-Year Update on Progression-Free Survival

Maher Salamoon

Poster Presenter: Maher Salamoon

Previous 1 2 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Preinduction With Azacitidine and Venetoclax in Newly Diagnosed Patients With Acute Myelogenous Leukemia: 3-Year Survival Update of a Comparative Study

AML - 639

Preinduction With Azacitidine and Venetoclax in Newly Diagnosed Patients With Acute Myelogenous Leukemia: 3-Year Survival Update of a Comparative Study

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups

AML - 643

Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

AML - 843

All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

CLL - 630

Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Treatment of higher risk Myelodysplastic Syndrome HR-MDS with high-dose chemotherapy followed by lenalidomide and azacitidine: a four-year survival update

MDS - 635

Treatment of higher risk Myelodysplastic Syndrome HR-MDS with high-dose chemotherapy followed by lenalidomide and azacitidine: a four-year survival update

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)

MDS - 644

The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)

Maher Salamoon

Poster Presenter: Maher Salamoon

Thumbnail for Treatment of high-risk smoldering multiple myeloma (HRSMM) with Isatuximab, lenalidomide, oral Cyclophosphamide and Dexamethasone: a survival advantage

MM - 633

Treatment of high-risk smoldering multiple myeloma (HRSMM) with Isatuximab, lenalidomide, oral Cyclophosphamide and Dexamethasone: a survival advantage

Maher Salamoon

Poster Presenter: Maher Salamoon

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors